

3/28/04
CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to The United States Patent and Trademark Office on the date set forth below.
Date Of Signature And Transmission: Oct 28, 03 Jean C. Baker
Jean C. Baker, Reg. No. 35,433

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FACSIMILE TRANSMISSION COVER SHEET

TO: Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Telecopy No. (703) 872-9307

RECEIVED
CENTRAL FAX CENTER

OCT 28 2003

FROM: Jean C. Baker, Esq.
Reg. No. 35,433
Attorney For Applicant
Quarles & Brady LLP
411 East Wisconsin Avenue
Milwaukee, Wisconsin 53202
Telephone No. (414) 277-5000
Telecopy No. (414) 271-3552

OFFICIAL

IN CASE OF PROBLEM, CALL (414) 277-5744

DATE: October 28, 2003

Applicant: Jeffrey Ross
Serial No.: 09/873,637
Filed: June 4, 2001
For: C-MYC CODING REGION DETERMINANT-BINDING PROTEIN
(CRD-BP) AND TIS NUCLEIC ACID SEQUENCE
Art Unit: 1642
Examiner: M. Yu

Client Matter No: 960296.98164
Job Code:
No. Pages:

Appl. No. 09/873,637
Amtd. Dated October 28, 2003
Reply to Office Action of September 8, 2003

Listing of Claims:

Please cancel claim 23.

Claims 1 – 15 (withdrawn)/

16. (Amended) A method of detecting breast cancer determining the presence or absence of anti-CRD-BP antibody in a patient's serum comprising the steps step of:

- a) exposing a patient's serum to CRD-BP and determining whether an anti-CRD-BP antibody is present.
- b) correlating the presence of anti-CRD-BP antibodies with breast cancer diagnosis.

Claims 17 – 20 (withdrawn).

21. (Previously Added) The method of claim 16 wherein the CRD-BP is recombinant.

22. (Amended) The method of claim 16 wherein the amount of anti-CRD-BP antibody is quantitated.

23. (Withdrawn) The method of claim 16 additionally comprising the step of correlating anti-CRD-BP antibody presence with cancer diagnosis.

Listing of Claims:

Please cancel claims 1-15, 17-20, 23 and 26.

Claims 1 – 15 (cancelled)

1. ~~16.~~ (currently amended) A method of detecting breast cancer comprising the steps of:

- a) obtaining a serum sample from a patient, exposing a patient's said serum to human CRD-BP and determining whether an anti-CRD-BP antibody is present in said serum; and *delete comma*
- b) correlating the presence of said anti-CRD-BP antibodies antibody with presence of breast cancer. *my*

Claims 17 – 20 (cancelled).

2. ~~21.~~ (previously presented) The method of claim ~~16~~ wherein the CRD-BP is recombinant.

3. ~~22.~~ (previously presented) The method of claim ~~16~~ wherein the amount of anti-CRD-BP antibody is quantitated.

23. (cancelled)

4. ~~24.~~ (previously presented) The method of claim ~~16~~ wherein the CRD-BP is bound to a solid support.

5. ~~25.~~ (previously presented) The method of claim ~~24~~ wherein the CRD-BP is exposed to serum and anti-CRD-BP antibody in the serum binds to the CRD-BP.

26. (cancelled)

6. ~~26.~~ (currently amended) The method of claim ~~26~~ ~~27~~ wherein the CRD-BP is radiolabeled and exposed to the serum, wherein the amount of radiolabeled CRD-BP bound to the solid support is measured.

QBMKE\5545952.1